Human Microbiome Global Forecast Report 2025 Market Set To Surge, Reaching USD 7.09 Billion By 2031 Driven By Personalized Medicine Demand

(MENAFN- GlobeNewsWire - Nasdaq) The Human Microbiome Market is projected to grow from USD 1.40 billion in 2024 to USD 7.09 billion by 2031, at a CAGR of 31.0%. This growth is driven by increasing collaboration between the microbiome industry and academia and rising demand for personalized medicine. The probiotics segment dominates the human microbiome supplements market in 2024, driven by their widespread use and established presence in health products. North America leads the market due to strong healthcare infrastructure and significant investment in microbiome research. However, complex regulatory policies continue to restrain market expansion. Key players include Seres Therapeutics and Ferring B.V.

Dublin, Sept. 08, 2025 (GLOBE NEWSWIRE) -- The "Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics, Diagnostics), Disease (Infectious, Gastrointestinal), Route (Oral, Rectal), CDMO (Formulation, Strain Engineering), Type (BCT/FMT, Live Bacteria) - Global Forecast to 2031" has been added to ResearchAndMarkets.com's offering.

The Human Microbiome market is projected to expand from USD 1.40 billion in 2024 to USD 7.09 billion by 2031, at an impressive CAGR of 31.0% during the forecast period. This growth is attributed to the increasing demand for personalized medicine and strategic collaborations between the microbiome industry and academic entities. Nevertheless, the market faces challenges in commercialization due to stringent regulatory policies.

The probiotics segment leads the human microbiome supplements market in 2024

The market is divided into human microbiome drugs, supplements, and diagnostics. Probiotics dominate the supplements segment due to their prominent application in digestive health, immunity enhancement, and gut microbial balance. The widespread consumer knowledge and established presence in OTC health products further bolster this segment's leadership. Their availability in accessible forms like capsules, powders, and functional foods boosts consumer adoption.

The gastrointestinal diseases segment holds the largest market share in 2024

A significant share of the human microbiome market is occupied by gastrointestinal diseases, owing to the link between gut microbiota and afflictions such as IBS, IBD, ulcerative colitis, and Crohn's disease. The high global prevalence of these chronic conditions drives the need for alternative therapies targeting the gut microbiome. Growing clinical evidence has spurred investment in microbiome-based diagnostics and therapies, enriching the segment's growth trajectory.

In 2024, North America dominates the human microbiome market

With a notable presence of key market players, cutting-edge healthcare infrastructure, and formidable investment in microbiome R&D, North America captures the largest market share. The region is home to numerous clinical trials and academic partnerships, particularly within the U.S. Regulatory backing, exemplified by the FDA's approval of products like VOWST and Rebyota, has paved the way for continual market advancement.

The comprehensive market research includes a diverse array of companies such as Seres Therapeutics (US), Ferring B.V. (Switzerland), BiomeBank (Australia), Seed Health, Inc. (US), and others. These key players contribute significantly to offering human microbiome drugs and supplements.

Key Benefits of Buying the Report

• Further analysis includes key drivers influencing the market, such as advancements in microbiome sequencing and the proliferation of startups exploring this niche.
• Innovative products in the microbiome sector and comprehensive market development analysis are highlighted to identify lucrative opportunities across different regions.
• The market diversification segment offers detailed information on untapped geographies, recent trends, and the latest investments in the Human Microbiome market.
• Competitive assessments cover companies like Seres Therapeutics, Ferring B.V., and International Flavors & Fragrances Inc., assessing their strategic initiatives and market positions.

Key Attributes:

Report Attribute	Details
No. of Pages	371
Forecast Period	2025 - 2031
Estimated Market Value in 2025	1.4 Billion
Forecasted Market Value by 2031	7.09 Billion
Compound Annual Growth Rate	31.0%
Regions Covered	Global

Key Topics Covered:
Market Dynamics

Drivers

• Collaborative Initiatives Between Organizations and Academia
• Increasing Number of Startups/SMEs Exploring Microbiome
• Advancements in Microbiome Sequencing

Restraints

• Complex Regulatory Policies
• High Investments in Commercializing Microbiome Drugs

Opportunities

• Increasing Demand for Personalized Medicines
• Emergence of Postbiotics

Challenges

• Slow Patient Adoption of Microbiome-based Therapies
• Complexities in Developing Microbiome Therapies

Case Studies

• Effect of Rebyota on Quality of Life in Patients with Recurrent Clostridioides Difficile Infection
• Ecospor IV Study of Vowst for Clostridioides Difficile Infection
• Delong Study for Quality of Life Improvement by Vsl#3 Probiotic in Post-COVID-19 Patients

Company Profiles

• International Flavors & Fragrances Inc.
• Seed Health, Inc.
• Seres Therapeutics
• Ferring B.V.
• Pendulum
• Optibiotix Health PLC
• Biogaia
• Maat Pharma
• Microba
• Biomebank
• Biohm Health
• Actial Farmaceutica Srl
• Resbiotic
• Infinant Health Inc.
• Exegi Pharma
• Finch Therapeutics Group, Inc.
• Infant Bacterial Therapeutics Ab
• Viome Lifesciences
• Genova Diagnostics
• Aobiome
• Guangzhou Zhiyi Biotechnology Co. Ltd.
• Nubiyota
• Oxthera
• Nexbiome
• Vedanta Biosciences, Inc.
• Enterome
• Apsen Farmaceutica
• Metagen, Inc.
• Snipr Biome
• Mikrobiomik
• Synlogic
• Genetic Analysis
• Metabiomics
• Sun Genomics, Inc.

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Human Microbiome Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN08092025004107003653ID1110029964